Showing 7341-7350 of 7643 results for "".
- LEO Pharma's Taclonex Topical Suspension Approved for Body Plaqueshttps://practicaldermatology.com/news/20121029-leo_pharma_receives_fda_approval_for_taclonex_topical_suspension/2459689/LEO Pharma Inc. announced the US Food and Drug Administration (FDA) approval of Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of body plaque psoriasis. Taclonex® Topical Suspension is
- Dermatologist Launches Rx Rebates, LLChttps://practicaldermatology.com/news/20121029-dermatologist_launches_rx_rebates_llc/2459690/Joel Bain Herron, MD, a dermatologist with Northeast Dermatology & Cosmetic Surgery Center, LLC in Gahanna, OH, founded Rx Rebates, LLC, a technology company. The website Rx_Rebates.com will be a mobile accessible site with a searchable database of digital versions of branded prescription rebate car
- Medical Entrepreneur Symposium Adds Breakout Sessionhttps://practicaldermatology.com/news/20121024-medical_entrepreneur_symposium_adds_breakout_session/2459693/The Medical Entrepreneur Symposium, a unique educational meeting for physicians, their office managers, and executives in healthcare, has added a breakout session for physician entrepreneurs wanting to take great business ideas or medical devices to market. Dr. Arlen Meyers will be the course direct
- ASDS Election Results Announcedhttps://practicaldermatology.com/news/20121023-asds_election_results_announced/2459696/The ASDS has elected new officers and members of its Board of Directors whose terms began at the recent annual meeting in Atlanta. Dr. George Hruza, Clinical Professor of Dermatology and Otolaryngology at St. Louis University, was elected Vice President and will ascend to President-Elect in 2013-14
- STELARA Wins 2012 International Prix Galien Awardhttps://practicaldermatology.com/news/20121022-stelara_wins_2012_international_prix_galien_award/2459698/Janssen Biotech, Inc. announced that STELARA was named the 2012 International Prix Galien award winner in Lyon, France. The honor is acknowledgment of the technical, scientific, and clinical research skills necessary to develop innovative medicines and devices. The international Prix Galien Award is
- Nuvo and Galderma Win FDA Approval for Topical Peelhttps://practicaldermatology.com/news/20121022-nuvo_and_galderma_win_fda_approval_for_topical_peel/2459699/Nuvo Research announced that the FDA has approved its Pliaglis product, a topical anesthetic cream designed to minimize pain during aesthetic dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. The approval
- TURO SKIN System Launchedhttps://practicaldermatology.com/news/20121018-turo_skin_system_launched/2459701/Founder and CEO John Renucci, MD, created TURO SKIN, a simplified skincare system for men, which has now been released. The collection offers solutions for face, shave, hair, and body. TURO SKIN products are available online at www.turoskin.com an
- The Medical Entrepreneur Symposium Adds New Session for Office Managershttps://practicaldermatology.com/news/20121017-the_medical_entrepreneur_symposium_adds_new_session_for_office_managers/2459702/The Medical Entrepreneur Symposium, a unique educational meeting for physicians, their office managers and executives in healthcare, has added an office manager focused breakout session called "Be A Better Office Manager." The symposium is based on the popularity of Dr. Steven Hacker's top-selling p
- New Fractionated Skin Resurfacing Module Enhances RF Laser Treatmentshttps://practicaldermatology.com/news/20121017-new_fractionated_skin_resurfacing_module_shortens_rf_laser_treatments/2459704/The PixelRF fractionated skin resurfacing module from Alma Lasers, Inc. uses proprietary InMotion Refractive Radiofrequency Micro Plasma Technology, which both ablates and heats the skin through controlled, focused delivery of energy without using disposables. The PixelRF was recently added to Alma'
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.